Table I.
Viability of FRO cells treated with various concentrations of 17-AAG at different time-points (mean ± SD, %).
| Concentration (µM) | 24 h (%) | 48 h (%) | 72 h (%) | F (P-value)a | P1b | P2b | P3b |
|---|---|---|---|---|---|---|---|
| 0.1 | 87.51±4.01 | 72.12±1.21 | 63.83±2.43 | 111.02 (<0.01) | <0.01 | <0.01 | 0.01 |
| 0.2 | 82.24±2.41 | 67.79±1.32 | 57.75±1.98 | 238.12 (<0.01) | <0.01 | <0.01 | <0.01 |
| 0.5 | 78.42±3.89 | 57.43±2.98 | 44.93±1.43 | 198.00 (<0.01) | <0.01 | <0.01 | <0.01 |
| 1 | 74.25±2.11 | 51.82±2.43 | 35.78±2.68 | 383.69 (<0.01) | <0.01 | <0.01 | <0.01 |
| 2 | 71.37±2.01 | 44.31±1.36 | 32.44±2.34 | 147.32 (<0.01) | <0.01 | <0.01 | <0.01 |
| 5 | 69.01±1.21 | 39.92±2.43 | 25.92±2.01 | 201.32 (<0.01) | <0.01 | <0.01 | <0.01 |
a
Analyzed by ANOVA.
b
Analyzed by a post hoc test (LSD method). P1, 24 vs. 48 h; P2, 24 vs. 72 h; P3, 48 vs. 72 h. 17-AAG, 17-allylamino-17-demethoxy-geldanamycin; ANOVA, analysis of variance; LSD, least significant difference.